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INTRODUCTION 
 
Cerebral small vessel disease (SVD) is a leading cause 
of cognitive decline and functional loss in the elderly 
[1]. Cerebral SVD is recognised by the resultant 
parenchymal lesions rather than the underlying small 
vessel alterations themselves, and typically manifests  
as lacunar lesions, diffuse white matter lesions 
(leucoaraiosis) and/or microbleeds. Accordingly, 
cerebral white matter hyperintensities (WMH) on MRI 
scan are recognised surrogates of cerebral SVD [1]. 
Although the aetiopathogenic mechanisms of cerebral 
SVD are unclear, there is a clear distinction from 
cerebral large vessel disease. Indeed, with the exception 
of hypertension, conventional cardiovascular risk 
factors such as diabetes and hyperlipidaemia have 
inconsistent correlation with cerebral SVD [2–5]. 
Further, after accounting for age and the traditional 
vascular risk factors, much of the variance in WMH 
volume remains unexplained [6]. 
 
Cerebral WMH predict incident stroke, dementia, heart 
failure, disability and mortality [1, 7]. Despite the lack of 
correlation with conventional cardiovascular risk factors 
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Introduction: Cerebral small vessel disease (SVD) is prevalent in the elderly population and is associated with 
increased risk of dementia, stroke and disability. Currently there are no clear targets or strategies for the 
treatment of cerebral SVD. We set out to identify modifiable vascular treatment targets. 
Patients and Methods: 112 participants with and without a history of CVD underwent macrovascular, 
microvascular and endothelial function tests and an MRI head scan. 
Results: Increased carotid intima media thickness and carotid-femoral pulse wave velocity were associated with 
cerebral WMH (β=1·1 p=0·001 and β=1·66, p<0·0001 respectively). Adjusted cerebral resistance index (p=0·03) 
and brachial flow mediated dilation time to peak (p=0·001) were associated with the severity of cerebral WMH 
independent of age and sex. Post occlusive reactive hyperaemia time as a measure of microvascular reactivity 
was associated with WMH after adjustment for age and sex (p=0·03). Ankle Brachial Pressure Index and urinary 
albumin excretion rate predicted the severity of cerebral WMH (p=0·02 and 0·01 respectively). Age and 
hypertension were the most important risk factors for WMH severity (p< 0·0001). 
Discussion: In addition to hypertension, microalbuminuria, arterial stiffness, vascular reactivity and 
cerebrovascular resistance could be potential treatment targets to halt the development or progression of 
cerebral SVD.  
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and with no supporting evidence base, current treatment 
strategies for managing cerebral WMH are extrapolated 
from the general management guidelines for the 
treatment of atherosclerotic disease. As a result, treatment 
strategies focusing on the use of antiplatelet, statins, 
aggressive blood pressure (BP) lowering and (in people 
with diabetes) aggressive glycaemic control may not be 
effective in the treatment of cerebral SVD [8, 9]. Indeed, 
the use of dual antiplatelet therapy is associated with a 
significantly increased risk of bleeding, whilst excessive 
BP lowering to targets of <130 mmHg is associated with 
cognitive decline in patients with cerebral SVD [10, 11]. 
The absence of specific treatments for cerebral SVD 
precipitates the need for clear targets or strategies for the 
treatment of cerebral SVD.  
 
We propose the search for such targets should  
focus on the underlying pathology of cerebral SVD, 
focusing specifically on the regulation of cerebral 
microcirculation. However, in order to identify 
potential treatment strategies, knowledge of the 
systemic correlates of cerebral SVD is required. As 
WMH are present in patients with and without history 
of previous CVD, we aimed to explore this in a 
general population sample of older adults enriched 




Of 169 potential participants screened, 57 were unable 
to undergo MRI (predominantly due to permanent 
pacemaker placement, surgical metal work or 
claustrophobia). The study therefore yielded 112 
participants with a full data set. The population 
characteristics are shown in Table 1. There were more 
males in the study (77 males vs. 35 female), however, 
there was no difference in WMH volume between the 
sexes (p=0.7). 
 
Association between vascular risk factors and WMH 
volume 
 
In univariate analysis, as anticipated, WMH volume 
was significantly higher in participants with history of 
hypertension compared to non-hypertensive individuals 
(4·5 cm3 (CI: 3·7 – 5·3) cm3 vs. 2·8 (CI: 2·3 – 3·4) cm3, 
p<0·0001). Further, aortic systolic BP and MAP (but 
not diastolic BP), aortic pulse pressure, ABPI were 
independently associated with WMH volume after 
adjustment for age and sex. Unsurprisingly, those 
recruited from stroke clinic had a higher WMH volume 
than the general population sample (4·4 (CI: 3·6 – 5·3) 
cm3 vs. 2·6 (CI 2·1 – 3·2) cm3, p=0·001). 
 
Cerebral WMH volume was associated with urinary 
albumin excretion rate, independent of age and sex. 
This was independent of diabetes, which only 
demonstrated a non-significant trend towards an 
association (5·3 (CI: 3·1 – 9·1) cm3 vs. 3·5 (CI: 3·0 – 
4·0) cm3 for those with and without diabetes 
respectively; p=0·09). There was no significant 
difference in the volume of WMH between smokers and 
non-smokers (3·4 (CI: 2·9 – 4·1) cm3 vs. 3·7 (CI: 3·0 – 
4·2) cm3 respectively; p=0·8).  
 
There was a paradoxical association between 
cholesterol and WMH, such that lower cholesterol was 
associated with higher WMH volume, but this is likely 
confounded by statin use in the population recruited 
from stroke clinic (Table 2). Of these variables, ABPI 
and urinary AER showed a trend towards predicting 
WMH after adjustment for aortic MAP, diabetes, lipids, 
smoking and alcohol volume (ß= -0·78, p=0·07 and ß= 
0·17, p=0·08 respectively). 
 
Association between vascular measurements and 
WMH volume 
 
As anticipated, a lower cerebral EDV was associated 
with increasing WMH volume (β= -0·9, p=0·02). 
However, this association was accounted for by age and 
sex (p=0·2). Cerebral PI and RI were associated with 
WMH (β=2·4 (CI: 1·3 – 3·6), p<0·0001 and β=6·0 (CI: 
3 – 9). P<0·0001 respectively) but this association was 
also attenuated by age and sex (p= 0·07 and 0·14 
respectively). ACRI, which accounts for differences in 
aortic BP, however, was positively associated with 
WMH volume independent of age and sex (β=0·9 (CI: 
0·08 – 1·6), p =0·03, adjusted β=0·72 (CI: -0·0004 – 
1·4), p=0·05). 
 
Carotid-femoral PWV (β=1·66 (CI: 0·97 – 2·3), p< 
0·0001) and carotid IMT (β=1·1 (CI: 0·42 – 1·7), 
p=0·001) were associated with WMH volume, although 
the latter of these was attributable to age and sex (p 
after adjustment=0·08).  
 
Brachial FMD and time to achieve maximal dilation, 
were both associated with WMH volume such that 
attenuated dilation and an increased time to achieve 
maximum dilation were associated with higher WMH 
volume. (β= -0·19 (CI: -0·37– (-0·003)), p=0·05 and 
0·9 (CI: 0·4 – 1·4), p=0·001 respectively). However, 
only time to achieve maximum dilation bore adjustment 
for age, sex (Adjusted β=0·65 (CI: 0·2 – 1·1, p=0·004). 
 
Similarly, and after adjustment for age and sex, a longer 
time to achieve microvascular peak PORH was 
associated with a higher WMH volume (Beta regression 
coefficient after adjustment = 0·3 (CI: 0·03 – 0·6), 
p=0·03). This was also independent of central MAP 
β=0·35 (CI: 0·08 – 0·63; p=0·012). No other measure 
www.aging-us.com 3 AGING 
Table 1. Population characteristics of study participants. 
Population characteristics 
Gender Males 77 (69%)  
Females 35 (31%) 
Age (years) 68 ± 9 
Systolic Blood pressure (mmHg) 130 ± 13 
Diastolic blood pressure (mmHg) 74 ± 8 
Diabetes  7 (6%) 
Treated hypertension 56 (50%) 
Ischaemic heart disease 13 (12%) 
Previous transient ischaemic attack 44 (39%) 
Previous stroke 31 (28%) 
Smoking 60 (54%) 
Alcohol > 15 units/week 25 (22%) 
Statins 74 (66%) 
Calcium channel blockers 18 (16%) 
ACE inhibitors 28 (25%) 
Beta blockers 11 (10%) 
Diuretics 22 (20%) 
Nitrates 1 (0.9%) 
Body Mass Index (kg/m2) 27 ± 4 
White matter hyper-intensities load (cm3) (IQ Range) 3·65 (2·0 – 6·0) 
 
Table 2. Linear regression analysis of vascular risk factors as predictors of WMH volume adjusted for age and 
sex. 
Parameter ß 95% CI R2 (%) P value 
P value adjusted for 
age and sex 
Age 0·04 0·02 – 0·06 22 <0·0001  
Systolic BP (mmHg)* 0·02 0·01 – 0·04 15 <0·0001 0·001 
Diastolic BP (Age ≥ 70) (mmHg)* 0·03 - 0·01 – 0·06 5 0·14 0·09 
Diastolic BP (Age < 70) (mmHg)* 0·03 0·01 – 0·04 10 0·007 0·008 
Mean Arterial Pressure (mmHg)* 0·025 0·01 – 0·04 8 0·003 0·001 
Pulse pressure (mmHg)* 0·033 0·02 – 0·05 17 <0·0001 0·004 
Ankle Brachial Pressure Index (ABPI) - 1·17 (- 2·1) – (-0·23) 6 0·02 0·04 
Weight (kg) 0·003 0·008 – 0·015 0·3 0·6 0·1 
Body Mass Index (kg/m2) 0·016 - 0·02 – 0·05 0·7 0·4  
Waist Hip Ratio (cm) 1·9 0·19 – 3·6 4 0·03 0·16 
Fasting glucose (mmol/L) 0·05 - 0·1 – 0·2 0·5 0·5  
HbA1c (mmol/L) 0·005 - 0·03 – 0·04 0·08 0·8  
Total Cholesterol (mmol/L) -0·14 -0·028 – 0·005 3 0·06 0·02 
Plasma viscosity (mPa.s) -0·12 - 2·4 – 2·2 0·01 0·9  
Alcohol (units per week) -0·007 - 0·03 – 0·01 0·4 0·5  
Creatinine (µmol/L) 0·5 - 0·18 – 1·2 0·25 0·01 0·14 
Albumin Excretion Rate (µg/min) 0·27 0·066 – 0·47 6·5 0·01 0·05 
ß, Beta regression coefficient; R2, variance explained by model, ABPI, Ankle brachial pressure index; *, central aortic pressure. 
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of microvascular function or endothelial independent 




In this study we explored the microvascular and 
macrovascular function of subjects with a range of 
cerebral SVD which is arguably different from the 
classic atherosclerotic picture seen in patient with large 
vessel disease and indeed could lend further support to 
the different physiological and epidemiological profiles 
of SVD and large vessel disease. This is characterised 
by a clear association between cerebral WMH and 
measures of microcirculatory autoregulation, namely 
cerebral vascular resistance. Further, there was an 
association with urinary AER, and both cerebral and 
peripheral microvascular reactivity. There was, 
however, no association between classic measures of 
endothelial function and cerebral WMH. This is 
contrary to findings in large vessel disease, suggesting a 
potential different mechanistic pathway of large vessel 
and small vessel disease [12]. It may also help to 
explain the lack of benefit seen in those with cerebral 
SVD when treated with therapies proven in large vessel 
disease and extrapolated onto this different disease 
process. As previously demonstrated, cerebral WMH 
was also tightly associated with BP and age [2]. This is 
in keeping with the reported benefit of good BP control 
in slowing the progression of cerebral WMH. 
 
The association of WMH with urinary AER is consistent 
with other studies [13, 14]. Microalbuminuria has also 
been shown to predict high risk transient ischaemic 
attacks [15]. For this reason therapies such as ACE 
inhibitors, angiotensin receptor antagonists or direct renin 
inhibitors, which are known to reduce microalbuminuria 
should be considered in order to reduce stroke risk [16]. 
In the general population, there is no additional benefit 
from a treatment regime based on ACE-inhibition versus 
calcium channel blocker or thiazide type diuretic [17]. 
This treatment strategy, however has not been formally 
tested for the management of cerebral small vessel 
disease. and requires further exploration [18]. 
 
The association of carotid IMT, accepted as a surrogate 
for atherosclerosis, with cerebral WMH was attenuated 
after adjustment for age and sex, contrary to what has 
been demonstrated elsewhere [8]. This could well be the 
effect of the relatively small study sample size, 
however, this is in keeping with the lack of benefit from 
statin therapy, the cornerstone of anti-atherosclerotic 
disease progression, seen in large studies of people with 
cerebral WMH [19]. Conversely, ABPI includes several 
contributions from macrovascular and microvascular 
function which probably explains its association with 
cerebral WMH demonstrated here. 
This is the first study that used the recognised 
surrogate markers of cutaneous microvascular function 
in patients with cerebral WMH. The association 
between systemic microvascular dysfunction, 
[impaired skin microvascular reactivity (PORH)], and 
cerebral WMH, provides additional evidence to 
support the suggestion that cerebral SVD is part of a 
systemic microvascular process [20, 21]. Further, this 
microcirculatory dysfunction may be part of a process 
eventually leading to end organ damage [20, 22, 23]. It 
is unlikely, however, that either process is completely 
independent, rather that end-organ damage is a result 
of a synergistic detrimental effect of microvascular 
and macrovascular disease precipitating both structural 
and functional changes. A greater knowledge of the 
longitudinal nature of these associations, and the 
interactions between the large and small vessels, will 
help determine appropriate treatment strategies 
focused on reducing progression of endothelial and 
microvascular dysfunction [24]. Isolating these novel 
targets may enable the slowing of pathogenic steps 
that lead to cerebral SVD and the subsequent adverse 
consequences on quality and quantity of life.  
 
Study strengths and limitations 
 
Our study strengths include the comprehensive 
assessment of the macrovascular, microvascular and 
endothelial function, never before performed in a 
single population. Further, we used automated 
volumetric assessment of the WMH volume which has 
accurate data and does not have a ceiling effect. The 
study limitations include a relatively small study 
population that could contribute to underpowered 
results, particularly in those results where the p value 
was borderline. A lack of humoral markers of 
endothelial and vascular function that would have 
added another dimension to this study is another 
limitation of this study. Further, the study participants 
were mainly recruited from two specific sources (TIA 
clinic/stroke unit and the Exeter 10,000 cohort) which 
could have inherently led to selection bias. Cerebral 
SVD is an umbrella term for a number of conditions 
and imaging findings (WMH, lacunar strokes, micro-
bleeds and perivascular spaces). In this study we 
mainly characterised WMH using the Freesurfer 
software which makes the results not generalizable to 
other forms of cerebral SVD. Another limitation of the 
study is the lack of dynamic cerebrovascular function 
indices (such as the breath holding test), this could 
have potentially added further information and helped 
better understand the functional reactivity of the 
cerebral circulation in patients with cerebral SVD, 
however the experience at our centre showed that these 
techniques are not well tolerated particularly by the 
older population. 
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Table 3. Regression analysis of vascular measurements as predictors of WMH volume (unadjusted and adjusted 
to age and sex). 
Parameter ß 95% CI R2 P value 
ß adjusted for 
age and sex 
P value adjusted 
for age, sex 
Carotid Femoral PWV (m/s) 1·66 0·97 – 2·3 0·18 <0·0001 1·0 0·01 
Intima Media Thickness (mm) 1·1 0·42 – 1·7 0·1 0·001 0·6 0·08 
Cerebral PSV (m/s) 0·02 - 0·08 – 0·88 0 1·0   
Cerebral EDV (m/s) -0·9 - 1·7 – (-0·12) 0·05 0·02 -0·5 0·2 
Cerebral MFV (m/s) -0·5 - 1·4 – 3·5 0·014 0·25   
Cerebral PI 2·4 1·3 – 3·6 0·16 <0·0001 1·3 0·07 
Cerebral RI 6·0 3 – 9 0·14 <0·0001 2·7 0·14 
Adjusted Cerebral Resistance 
Index (ACRI) 
0·9 0·08 – 1·6 0·05 0·03 0·7 0·05 
Flow Mediated Dilation (%) -0·19 -0·37– (-0·003) 0·04 0·05 -0·07 0·4 
FMD Time to Peak (s) 0·9 0·4 – 1·4 0·14 0·001 0·65 0·004 
Ach Peak Response (flux units) 0·3 - 0·4 – 1·0 0·01 0·4   
Ach AUC 0·15 - 0·3 – 0·6 0·005 0·5   
PORH peak response -0·09 -0·4 – 0·23 0·003 0·6  1.0 
PORH Time to Peak (s) 0·18 -0·15 – 0·5 0·01 0·3 0·3 0·03 
PORH hyperaemia duration (s) -0·02 -0·3 – 0·26 0·0002 0·9  0·4 
ß, Beta regression coefficient; R2, variance explained by model; PWV, pulse wave velocity; PSV, peak systolic velocity; EDV, 
end diastolic velocity; MFV, mean flow velocity; PI, Pulsatility index; RI, resistive index; FMD, flow mediated dilation; Ach, 




Patients with cerebral WMH have a poor vascular 
function profile. This is the first study to undertake a 
comprehensive evaluation of the function of the 
vascular tree and its association with cerebral WMH. 
We identified micro and macro vascular markers that 
are associated with cerebral WMH. Longitudinal work 
is required to determine whether modulation of these 
parameters can slow or even halt progression of cerebral 
SVD.  
 




The study protocol was developed in line with the 
Helsinki declaration revised 1983. The protocol was 
approved by the local ethics committee (Southwest 
local ethics committee, UK). Patients with history of 
TIA and Stroke were recruited from the TIA clinic and 
the stroke unit (The Royal Devon and Exeter Hospital). 
A general population sample (age and gender matched) 
was recruited from a research register (the Exeter 
10,000) of individuals from the Exeter community who 
volunteered to take partpart in research. This was to 
generate a study population with a range of cerebral 
small vessel disease with and without history of 
TIA/Stroke. 
All participants gave written, informed consent and 
completed a questionnaire on demographics, medical 
history, medications and lifestyle behaviours. Participants 
who had a known contraindication for MRI were 
excluded from the study. Anthropometry including 
height, weight, ankle brachial pressure index (ABPI) and 
waist hip ratio was measured according to a standard 
protocol. Blood and urine samples were analysed by the 
on-site laboratory, which is a member of the appropriate 
UK National Quality Assessment Scheme.  
 
At a separate visit macrovascular, microvascular and 
endothelial function were assessed after an overnight 
fast, from 10 pm the night before. All participants were 
requested to refrain from consuming coffee, tea, other 
caffeinated drinks, alcohol, medication and strenuous 
exercise to minimise the variance on vascular studies. 
All studies commenced at 9am after a standardised 
breakfast to minimise the effect of diurnal variation on 




Carotid artery ultrasound 
The common carotid arteries were assessed non-
invasively using a Doppler ultrasound machine with a 
high-resolution linear array transducer (SSD-5500 SV, 
Aloka, Tokyo, Japan) previously described elsewhere 
[25]. Briefly, subjects lay supine on an examination bed 
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with the head turned ~45° away from the examined side. 
The B-mode common carotid artery images taken at the 
R wave of the ECG with satisfactory quality were stored 
in the ultrasound machine, and were downloaded later 
for off-line analysis. Lumen diameter and intima-media 
thickness (IMT) were analysed using semi-automated 
edge-detection software (Artery Measurement System: 
ver 2·02, Gothenburg, Sweden) [26]. The software 
automatically identified a 10 mm-long segment from the 
beginning of the bulb of the near wall-lumen boundary 
and the far wall IMT of the common carotid artery free 
from plaques. A plaque was defined as >50% increase in 
IMT compared to adjacent IMT. This automated 
analysis could be adjusted manually if the identification 
of borders was not appropriate. IMT was defined as the 
height between the lumen-intima and the media-
adventitia borders at the far wall. Data from the right and 
left sides of the common carotid arteries were averaged, 
and mean values were used for statistical analysis for 
both variables.  
 
Brachial artery flow-mediated dilation 
Brachial artery endothelium-dependent dilation (FMD) 
was assessed noninvasively following established 
guidelines [27, 28] and previously described by us 
elsewhere [29–31]. Briefly, subjects lay supine on an 
examining bed with the right arm supported and fixed in 
position using a positioning pillow on a metal table. The 
same Doppler ultrasound machine was used to obtain a 
B-mode ultrasound image of the brachial artery. To 
elicit reactive hyperaemia, an appropriately-sized cuff 
selected for the subject was placed around the forearm 
and inflated to 250 mmHg for 5 min using a rapid cuff 
inflation system (AI6; Hokanson, Bellevue, WA, USA). 
Brachial artery images were recorded for 60 cardiac 
cycles at baseline. The recording was restarted 30 sec 
before cuff deflation and continued for 3 min post-
deflation. All brachial artery images were recorded and 
analysed by the same investigator using dedicated 
software (Vascular Research Tools, version 5.8.6, 
Medical Imaging Applications LLC, Coralville, IA, 
USA). FMD was calculated as the maximum percentage 
changes in diameter after cuff deflation compared to 
baseline diameter, and the time to achieve peak dilation 
was recorded from the time of cuff deflation. 
 
Transcranial doppler (TCD) 
A trained researcher used an approved power-mode 
TCD unit with a 2-MHz probe at 100% power and a 10-
mm sample volume for the examination (Nicolet 
Companion III; VIASYS Healthcare). A standard 
insonation protocol was used. An insonation depth of 
45–65 mm was used to identify the M1 segment of the 
middle cerebral artery (MCA) through the trans-
temporal window. An optimal signal was defined as one 
that had a clear spectral wave form and trace envelope 
that follow the wave form throughout the recording with 
no noise artefacts. Cerebral blood flow parameters 
including peak systolic velocity (PSV), end diastolic 
velocity (EDV) and mean systolic velocity (MFV) were 
measured according to standard protocol [32]. Static 
cerebrovascular resistance was estimated using the 
pulsatility index (PI) (PI = PSV – EDV / MFV) and the 
resistive index (RI) (RI= PSV – EDV / PSV). Dynamic 
cerebrovascular resistance was calculated by adjusting 
cerebral mean blood flow velocity (MFV) to central 
mean arterial pressure (cMAP) and is presented as 
adjusted cerebrovascular resistance index (ACRI) of 
cMAP/MFV [33]. 
 
Pulse wave velocity (PWV) and pulse wave analysis 
(PWA)  
Carotid-femoral pulse wave velocity was assessed non-
invasively using applanation tonometry (SphygmoCor 
ver 8·2, AtCor Medical, Sydney, Australia), sequentially 
recording ECG-gated waveforms at the carotid and 
femoral sites. Radial artery waveforms were recorded 
using a high-fidelity pressure transducer, and then used 
to generate corresponding aortic pressure waveforms by 
using a generalized transfer function which has been 
validated previously [34]. All measurements including 
aortic-femoral PWV, aortic systolic BP, aortic diastolic 
BP, aortic mean arterial pressure (MAP) and aortic pulse 
pressure were made in triplicate by trained investigators 




Post-occlusive reactive hyperaemia (PORH) 
Microvascular assessments were conducted as previously 
reported [35–37] on the dorsum of the foot. Reactive 
hyperaemia was assessed by ischemia-reperfusion, 
induced by 4 minutes of supra-systolic cuff-inflation 
around the ankle until pulsatile flow is terminated. 
Perfusion measurements were obtained for five minutes 
at baseline and five minutes after cuff release.  
 
Iontophoresis of acetylcholine (Ach) and sodium 
nitroprusside (SNP) 
This method has been described elsewhere [38]. Laser 
Doppler Perfusion Imaging (LDPI, MoorLDI, Moor 
Instruments, Axminster, UK) was used to measure the 
cutaneous flux response to the iontophoretic delivery of 
Acetylcholine (ACh, endothelium dependent response) 
and Sodium Nitroprusside (SNP, endothelium 
independent response). ACh (1% ACh in mannitol, 
Michol-E, Bausch and Lomb Inc, Germany) or its control 
(3% mannitol in water) was delivered using an anodal 
current (5 x 0·1 mA for 20 seconds with a 60 second 
interval between each dose, resulting in a total charge of 
10mC) (DRT4, Moor Instruments, Axminster, UK). SNP 
(0·25%: 25 mg/ml Nitropress, Hospira, USA in 0·45% 
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NaCl w/v saline, Baxter UK, Norfolk, UK) or control 
vehicle (0·45% NaCl) was delivered using a cathodal 
charge (1 x 0·2 mA for 60 seconds, resulting in a total 
charge of 12 mC). Cutaneous flux was assessed by LDPI 
at rest and then every 20 seconds following the start of 
the iontophoresis charge for a total of 7 mins with Ach 
and 6 mins for SNP. The mean cutaneous flux was 
determined over an area of 0·78 cm2 (Moor software). 
The data are expressed as peak and total response (area 
under the curve, normalised for resting blood flux). 
 
Magnetic resonance imaging (MRI) 
 
An MRI scan of the brain was performed on a different 
visit in order to calculate WMH volumes. All MRI 
images were acquired using a 1·5 Tesla scanner 
(Philips, The Netherlands) using an 8 channel head coil. 
After initial survey images T1 structural images of the 
brain with an axial oblique orientation were acquired. 
All images were examined for quality.  
 
Cortical reconstruction and volumetric segmentation 
was performed with the Freesurfer image analysis suite 
(Freesurfer version 5·1·0, Athinoula A. Martinos Center 
for Biomedical Imaging, Charlestown, Massachusetts), 
which is documented and freely available for download 
online (http://surfer.nmr.mgh.harvard.edu/). All 
Freesurfer images were examined by an independent 
researcher for accurate volume reconstruction and 




Data were treated as continuous variables wherever 
possible to maximize power. All normally distributed 
data are presented as mean ± SD. Skewed data were 
appropriately log transformed and presented as 
geometric means (95% CI). Statistical significance for 
categorical variables was calculated using the chi-
squared test and the Student’s t-test for continuous 
variables. WMH volume was treated as a continuous 
variable in all study participants. A linear regression 
model was used to explore the association between 
cerebral WMH and variables of interest. To explore 
independent determinants of associations between 
variables, multinomial logistic regression analysis was 
used. Age, sex and blood pressure (MAP) were forced 
into the final model, as these all have an established 
effect on cerebral vascular autoregulation. To assess  
the best vascular measurement (microvascular, 
macrovascular, endothelial and cerebral blood flow 
parameters) that predicts WMH volume we used a multi 
variable regression model. Alpha was P≤0·05. In 
keeping with the recommendations of Cupples (Cupples 
et al., 1984) and Rothman (Rothman, 1990) for 
performing hypothesis driven analyses, significance of 
the variables of interest is reported without adjustment 
for multiple testing. Any additional variables in these 
models (although not reported here) should be subject to 
such Bonferroni correction. Statistical analysis was 
performed using Stata SE 13·0 (Microsoft version: 




Ach: Acetylecholine; ABPI: Ankle Brachial Pressure 
Index; BP: Blood Pressure; CVD: Cerebrovascular 
diseases; EDV: End Diastolic Velocity; FMD: Flow 
Mediated Dilation; IMT: Intima Media Thickness; MAP: 
Mean Arterial Pressure; cMAP: Central Mean Arterial 
Pressure; MFV: Mean Flow Velocity; MRI: Magnetic 
Resonance Imaging; PORH: Post Occlusive Reactive 
Hyperaemia; PSV: Peak Systolic Velocity; PWV: Pulse 
Wave Velocity; SNP: Sodium Nitroprusside; SVD:  
Small vessel disease; TCD: Transcranial Doppler; 
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